Azuriya Pharma was formed to advance APX3330 — an asset that has been shepherded through more than $100 million of prior development across Apexian, Eisai, and Ocuphire — into the indication it was always best suited for: Inflammatory Bowel Disease.
More than half of the 7 million people living with Inflammatory Bowel Disease worldwide never achieve durable remission. For decades, the industry has focused on downstream cytokine blockade — each new generation achieving incremental improvements while leaving the root drivers of disease untouched.
APX3330 is the first oral therapy to act upstream of NF-κB, HIF-1α, STAT3, and AP-1 — without additive immunosuppression. Our mandate is to rapidly prove the mechanism in patients, establish a clean regulatory path, and deliver an oral that pharma partners can combine with existing classes to close the remission gap.
Over 30 years of leadership in biotechnology as a serial entrepreneur, investor, and CEO. Extensive experience in private and public capital raises, corporate governance, and advancing clinical-stage assets across multiple therapeutic areas.
Over 30 years of experience in translational science spanning oncology, ophthalmology, IBD, and drug discovery. Founder and CSO of Apexian Pharmaceuticals since 2008. Author on numerous peer-reviewed publications establishing Ref-1 as a therapeutic target.
Over 25 years of experience across drug discovery and development, including CMC, nonclinical, and regulatory strategy through NDA. Inventor of Esperion's approved LDL-lowering therapy Nexletol. Working with APX3330 since 2020.
Over 30 years of executive leadership with a proven track record of capital raises, board leadership, and successful exits to large pharma and private equity. Prior experience includes Pfizer, Eli Lilly, Yamatake, Arlington Capital, AKKR Searchlight, and Genstar.
Founder-led board with independent directors drawn from clinical development, pharma business development, and capital markets. Committee structure aligned to Nasdaq corporate governance standards in anticipation of a public listing pathway.
KOL engagement across gastroenterology and translational science. Formal SAB formation underway in parallel with Phase 2a site selection and protocol design in Australia.
Lean core team augmented by CRO and CDMO partnerships. Australian subsidiary for CTN submission and P2a execution. Full-scale P2b run in AUS + US through established site network.
We welcome conversations with KOLs, business development leaders, and investors evaluating the next wave of IBD innovation.
Get in Touch →